HELPHelus Pharma Inc.

Helus Pharma said it completed enrollment ahead of schedule in the Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder.

A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening PR Newswire NEW YORK and TORONTO, July 21, 2026 Issued on behalf of...

Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates PR Newswire NEW YORK, July 21, 2026 Major Depressive Disorder Market Poised for Strong Growth as New Drug Innovations...

H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.

Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time PR Newswire NEW YORK, July 17, 2026 Issued on...

Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity   New York, NY – June 30, 2026 – Market News Updates News Commentary – The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on traditional antidepressants that often […] The post Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity appeared first on Financial News Media.

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year PR Newswire NEW YORK and TORONTO, June 26, 2026 Issued on behalf of Helus PharmaHelus Pharma...

– APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment – – Phase 2 HLP003 data demonstrated long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale (“MADRS”) score compared to baseline at 12 months after two 16 mg […] The post FNM News Break: Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress appeared first on Financial News Media.

Cybin (NASDAQ:HELP) Shares Up 2.7% - Should You Buy...